Hide metadata

dc.date.accessioned2023-03-16T16:17:48Z
dc.date.available2023-03-16T16:17:48Z
dc.date.created2022-11-17T13:08:54Z
dc.date.issued2022
dc.identifier.citationAghcheli, Bahman Behboudi, Emad Tabarraei, Alijan Razavi Nikoo, Hadi Rajabi, Abdolhalim Moradi, Abdolvahab Nakstad, Britt Tahamtan, Alireza . Serum cytokine/chemokine profile and clinical/paraclinical data in COVID-19 deceased and recovered patients. European Journal of Inflammation. 2022, 20, 1-16
dc.identifier.urihttp://hdl.handle.net/10852/101528
dc.description.abstractObjectives: The induction of an intense immune response and cytokine storm is proposed to be central in the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study evaluated serum cytokine/chemokine profiles, and clinical and paraclinical data of COVID-19 deceased and recovered patients in Iran. Methods: The severity of disease, clinical data, and routine laboratory and inflammatory cytokine/chemokine responses were retrospectively explored in 60 in-hospital patients in northern Iran. Characteristics of those who deceased ( n = 30) were compared to recovered ( n = 30), and associations with serum levels of potential disease regulating pro- and anti-inflammatory mediators were studied. Results: The serum levels of IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-17, IP-10, MIP1-α, MCP1, RANTES, and TNF-α were upregulated in all COVID-19 patients when compared to healthy and gender-matched individuals ( n = 30). Although with no significant difference between deceased and recovered cases, the serum levels of all cytokines/chemokines tended to be higher in the severely diseased non-surviving patients. Association analyses revealed that all cytokine/chemokine levels (except IL-10) significantly affect the disease outcome. Conclusion: This study provides more evidence for the association of cytokine/chemokine levels with the clinical course and outcome of COVID-19. More studies are needed to consider this measurement as an indicator of disease stage and strategy for treatment.
dc.languageEN
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.titleSerum cytokine/chemokine profile and clinical/paraclinical data in COVID-19 deceased and recovered patients
dc.title.alternativeENEngelskEnglishSerum cytokine/chemokine profile and clinical/paraclinical data in COVID-19 deceased and recovered patients
dc.typeJournal article
dc.creator.authorAghcheli, Bahman
dc.creator.authorBehboudi, Emad
dc.creator.authorTabarraei, Alijan
dc.creator.authorRazavi Nikoo, Hadi
dc.creator.authorRajabi, Abdolhalim
dc.creator.authorMoradi, Abdolvahab
dc.creator.authorNakstad, Britt
dc.creator.authorTahamtan, Alireza
cristin.unitcode185,53,46,0
cristin.unitnameBarne- og ungdomsklinikken
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2075595
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European Journal of Inflammation&rft.volume=20&rft.spage=1&rft.date=2022
dc.identifier.jtitleEuropean Journal of Inflammation
dc.identifier.volume20
dc.identifier.doihttps://doi.org/10.1177/1721727X221125436
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn1721-727X
dc.type.versionPublishedVersion
cristin.articleid1721727X2211254


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial 4.0 International
This item's license is: Attribution-NonCommercial 4.0 International